← 返回

IL-6 和 MSH3 在结直肠癌中的表达、关系及在 171 例结直肠癌病例中的预后意义

英文原题:Il-6 and MSH3 in colorectal carcinoma: Expression, relationship, and prognostic significance in 171 colorectal carcinoma cases.

查看英文原题

Il-6 and MSH3 in colorectal carcinoma: Expression, relationship, and prognostic significance in 171 colorectal carcinoma cases.

PubMed 2024/05/10(内容时间) Indian J Pathol Microbiol Q4 · IF 0.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究未显示 IL-6 与 MSH3 表达之间存在关联。由于 MSH3 是一种相对鲜为人知的蛋白,需要进一步开展大规模研究。未来使用 IHC 来识别可能从抗 IL-6 治疗中获益的 CRC 患者可能至关重要。

研究思路结论见上方概要

结直肠癌(CRC)是胃肠道最常见的癌症类型,其发生大多由环境因素导致。炎症在其病因中相对少见但却是重要的促成因素,而且炎症也被认为在没有临床诊断炎症性肠病的患者中构成风险。在细胞系中,促炎细胞因子白细胞介素-6(IL-6)导致错配修复蛋白MSH3发生胞质转移,并伴随功能丧失。本研究旨在通过免疫组织化学(IHC)评估171例散发性CRC样本中IL-6和MSH3的表达。假设高水平的IL-6会导致MSH3表达缺失。我们还探讨了IHC检测到的MSH3缺失的临床/病理学方面,以及MSH3表达与TIL(肿瘤浸润淋巴细胞)(TILs)之间的关系。

IL-6和MSH3 IHC以及H和E切片由两名病理学家评估。临床数据从该机构数据库中获取。

MSH3缺失与IL-6表达之间的关系未得到证实(P = 0.963)。在TILs高的患者组中,MSH3染色显著降低(P = 0.035)。我们观察到104例CRC病例(60.8%)存在IL-6表达,85例(49.7%)存在MSH3表达降低。

展开英文摘要原文

IL-6 and MSH3 IHC and H and E slides were evaluated by two pathologists. Clinical data were obtained from the institution's database.

A relationship between MSH3 loss and IL-6 expression was not proven ( P = 0.963). MSH3 staining was significantly reduced in the patient group with high TILs ( P = 0.035). We observed 104 CRC cases (60.8%) with IL-6 expression and 85 cases (49.7%) with reduced MSH3 expression.

This study did not demonstrate an association between IL-6 and MSH3 expression. As MSH3 is a relatively little-known protein, further large-scale studies are needed. The use of IHC to identify patients who may benefit from anti-IL-6 therapies in CRC in the future may be critical.

论文信息

作者
Kolay Bayram E、Ogut B、Inan MA、Dursun A
第一作者单位
Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.Turkey
期刊
Indian journal of pathology & microbiology2024 Oct 1
原文标识
PubMed 38727512 · DOI 10.4103/ijpm.ijpm_633_23